Evidence map›Paper›PMID 33535790›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2021

Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: A National Population-Based Cohort Study.

Hae-Young Lee, Juhee Ahn, Juhong Park, Chang Kyung Kang, Sung-Ho Won, Dong Wook Kim, Jong-Heon Park, Ki-Hyun Chung, Joon-Sung Joh, Ji Hwan Bang and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Immunomodulatory effects of atorvastatin on MRL/lpr mice.Advances in rheumatology (London, England) · 2022
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Review
  20. Circulating Lipids and COVID-19: Insights From Mendelian Randomization.Arteriosclerosis, thrombosis, and vascular biology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Hae-Young Lee *Korean Society of Hypertension (H.-Y.L., W.B.P.).
Juhee Ahn *Department of Public Health Sciences (J.A., J.P., S.-H.W.), Seoul National University, Korea.
Juhong ParkDepartment of Public Health Sciences (J.A., J.P., S.-H.W.), Seoul National University, Korea.
Chang Kyung KangDepartment of Internal Medicine, Seoul National University Hospital, Korea (H.-Y.L., C.K.K., M.-d.O).
Sung-Ho WonDepartment of Public Health Sciences (J.A., J.P., S.-H.W.), Seoul National University, Korea.
Dong Wook KimNational Health Insurance Service, Wonju, Korea (D.W.K., J.-H.P., C.H.K.).
Jong-Heon ParkNational Health Insurance Service, Wonju, Korea (D.W.K., J.-H.P., C.H.K.).
Ki-Hyun ChungNational Medical Center, Seoul, Korea (K.-H.C., J.-S.J.).
Joon-Sung JohNational Medical Center, Seoul, Korea (K.-H.C., J.-S.J.).
Ji Hwan BangCentral Infectious Disease Hospital, Seoul, Korea (J.H.B.).
Cheong Hee KangNational Health Insurance Service, Wonju, Korea (D.W.K., J.-H.P., C.H.K.).
Wook Bum PyunKorean Society of Hypertension (H.-Y.L., W.B.P.).
Myoung-Don OhKorean Society of Hypertension (H.-Y.L., W.B.P.).
Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases
Seoul National University · KREuropean Society of Hypertension · ITNational Clinical Research · USSeoul National University Hospital · KRNational Health Insurance Service · KRNational Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAlthough statins are widely prescribed lipid-lowering drugs, there are concerns about the safety of their use in the context of coronavirus disease 2019 (COVID-19), since statins increase the expression of ACE2 (angiotensin-converting enzyme 2). This study aimed to disclose the association between statins and 60-day COVID-19 mortality. Approach and Results: All patients hospitalized with laboratory-confirmed COVID-19 were enrolled in this study from January 19 to April 16, 2020, in Korea. We evaluated the association between the use of statins and COVID-19-related mortality in the overall and the nested 1:2 propensity score-matched study. Furthermore, a comparison of the hazard ratio for death was performed between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia between January and June 2019 in Korea. The median age of the 10 448 COVID-19 patients was 45 years. Statins were prescribed in 533 (5.1%) patients. After adjusting for age, sex, and comorbidities, Cox regression showed a significant decrease in hazard ratio associated with the use of statins (hazard ratio, 0.637 [95% CI, 0.425-0.953];

conclusionsThe use of statins correlates significantly with lower mortality in patients with COVID-19, consistent with the findings in patients with pneumonia. Graphic Abstract: A graphic abstract is available for this article.

Indexed as

COVID-19 Drug TreatmentPandemicsSARS-CoV-2AdolescentAdultAgedAged, 80 and overChildChild, PreschoolCohort StudiesCOVID-19Diabetes ComplicationsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionHydroxymethylglutaryl-CoA Reductase Inhibitorscohort studiesCOVID-19hydroxymethylglutaryl-CoA reductase inhibitorsmortalitypropensity score

Identifiers

PMID33535790
PMCPMC7901529
OpenAlexW3126834053

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.